FIRST AMENDMENT TO LICENSE AGREEMENTLicense Agreement • May 14th, 2024 • Nuvation Bio Inc. • Pharmaceutical preparations
This first amendment (the "First Amendment") to License Agreement (later defined) is made as of August 17, 2020 ("First Amendment Effective Date") by and between Daiichi Sankyo Company, Limited, a Japanese corporation having an office and principal place of business at 5-1, Nihonbashi-honcho 3-chome Chuo-ku, Tokyo 103-8426, Japan ("Daiichi Sankyo") and AnHeart Therapeutics Inc., a Delaware corporation having an office and place of business at 5 Penn Plaza 23rd floor, New York, NY 10001, USA ("AnHeart"). Daiichi Sankyo and AnHeart are each referred to herein individually as a "Party," or collectively as "Parties". As used in this First Amendment, capitalized terms, whether used in the singular or plural, shall have the respective meanings set forth in the License Agreement.
LICENSE AGREEMENT BETWEEN DAIICHI SANKYO COMPANY, LIMITED AND ANHEART THERAPEUTICS INC.License Agreement • May 14th, 2024 • Nuvation Bio Inc. • Pharmaceutical preparations • New York
This License Agreement (the “Agreement”), dated the 7th day of September, 2020 (the “Effective Date”), is between DAIICHI SANKYO COMPANY, LIMITED, a Japanese corporation having an office and principal place of business at 5-1, Nihonbashi-honcho 3-chome Chuo-ku, Tokyo 103-8426, Japan (“Daiichi Sankyo”), and, ANHEART THERAPEUTICS INC., a Delaware corporation having an office and place of business at 5 Penn Plaza, 23rd floor, New York, NY 10001, USA (“AnHeart”). Daiichi Sankyo and AnHeart are each referred to herein by name, individually as a “Party” or collectively as “Parties”.
LICENSE AGREEMENT BETWEEN DAIICHI SANKYO COMPANY, LIMITED AND ANHEART THERAPEUTICS INC.Exclusive License Agreement • May 14th, 2024 • Nuvation Bio Inc. • Pharmaceutical preparations • New York
This License Agreement (the “Agreement”), dated the 7th day of December, 2018 (the “Effective Date”), is between DAIICHI SANKYO COMPANY, LIMITED, a Japanese corporation having an office and principal place of business at 5-1, Nihonbashi-honcho 3- chome Chuo-ku, Tokyo 103-8426, Japan (“Daiichi Sankyo”), and ANHEART THERAPEUTICS INC., a Delaware corporation having an office and place of business at 5 Penn Plaza, 23rd floor, New York, NY 10001, USA (“AnHeart”). Daiichi Sankyo and AnHeart are each referred to herein by name, individually as a “Party”, or collectively as “Parties”.
